{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:37:54Z","timestamp":1760549874613,"version":"3.40.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011892","name":"Kaohsiung Chang Gung Memorial Hospital","doi-asserted-by":"crossref","award":["CMRPG891711","CMRPG8C1301"],"award-info":[{"award-number":["CMRPG891711","CMRPG8C1301"]}],"id":[{"id":"10.13039\/501100011892","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jfma.2015.09.003","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T21:48:49Z","timestamp":1445809729000},"page":"83-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor-\u03b1 therapy in clinical practice"],"prefix":"10.1016","volume":"115","author":[{"given":"Meng-Ju","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaw-Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hsia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Yi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Lin","family":"Tain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ching Lily","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-528X","authenticated-orcid":false,"given":"Chien-Ning","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2015.09.003_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1378\/chest.118.2.503","article-title":"Proinflammatory cytokines","volume":"118","author":"Dinarello","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2015.09.003_bib2","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2165\/00003495-200464240-00005","article-title":"Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis","volume":"64","author":"De Keyser","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jfma.2015.09.003_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2015.09.003_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15060","article-title":"A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-\u03b1) inhibitors, adalimumab and infliximab, for Crohn's disease","volume":"15","author":"Dretzke","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jfma.2015.09.003_bib5","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2165\/00003495-200262170-00013","article-title":"Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis","volume":"62","author":"Culy","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jfma.2015.09.003_bib6","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2015.09.003_bib7","first-page":"10","article-title":"Disease modifying antirheumatic drugs: longterm safety issues","volume":"62","author":"Capell","year":"2001","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jfma.2015.09.003_bib8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2015.09.003_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2015.09.003_bib10","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2015.09.003_bib11","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","article-title":"Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan","volume":"17","author":"Ke","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jfma.2015.09.003_bib12","unstructured":"Food and Drug Administration, Ministry of Health and Welfare in Taiwan. Risk communication letter for TNF-alpha blockers (No. 1001403067), 6\/1\/2011. Available from: http:\/\/www.tshp.twmail.net\/index.php?option=com_content&view=article&catid=51%3A2010-01-12-11-25-17&id=474%3A2011-06-13-06-13-52&Itemid=1. [last accessed 18.08.15]. [In Chinese]."},{"key":"10.1016\/j.jfma.2015.09.003_bib13","unstructured":"Food and Drug Administration, Ministry of Health and Welfare in Taiwan. Risk communication letter for TNF-alpha blockers (No. 1001404956), 8\/25\/2011. Available from: http:\/\/www.nhi.gov.tw\/webdata\/webdata.aspx?menu=21&menu_id=713&webdata_id=1975. [last accessed 22.08.14]. [In Chinese]."},{"key":"10.1016\/j.jfma.2015.09.003_bib14","unstructured":"Food and Durg Administration, Ministry of Health and Welfare in Taiwan. Risk management plan of TNF-alpha blockers (No. 1001405934), 4\/2\/2012. Available from: http:\/\/www.fda.gov.tw\/tc\/newsContent.aspx?id=8588&chk=e77f64db-d352-47ce-99db-5cffe0aa3d78&param=pn%3d19%26cid%3d3%26cchk%3d46552e96-810a-42c3-83e1-bd5e42344633%26y%3d2012#.U__yUJ6wrIU. [last accessed 22.08.14]. [In Chinese]."},{"key":"10.1016\/j.jfma.2015.09.003_bib15","first-page":"8","article-title":"Screening and management of tuberculosis infection in patients scheduled for tumor necrosis factor-alpha inhibitors consensus recommendations from the Taiwan Rheumatology Association","volume":"26","author":"Chen","year":"2012","journal-title":"Formos J Rheumatol"},{"key":"10.1016\/j.jfma.2015.09.003_bib16","first-page":"1","article-title":"Screening and management of hepatitis B infection in rheumatic patients scheduled for biologic therapy: consensus recommendations from the Taiwan Rheumatology Association","volume":"26","author":"Chen","year":"2012","journal-title":"Formos J Rheumatol"},{"key":"10.1016\/j.jfma.2015.09.003_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jfma.2014.03.003","article-title":"External review of the National Tuberculosis Program and the development of strategy and targets post 2015 in Taiwan","volume":"113","author":"Chan","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2015.09.003_bib18","unstructured":"Ministry of Health and Welfare. 2012 Statistics of causes of death. Available from: http:\/\/www.mohw.gov.tw\/EN\/Ministry\/Statistic.aspx?f_list_no=474&fod_list_no=3523. [last accessed 25.07.14]."},{"key":"10.1016\/j.jfma.2015.09.003_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","article-title":"Minimization of hepatitis B infection by a 25-year universal vaccination program","volume":"57","author":"Ni","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2015.09.003_bib20","unstructured":"Chang Gung Medical Foundation. Status of medical services from 2009 to 2013. Available from: https:\/\/www.cgmh.org.tw\/eng2002\/index.asp. [last accessed 10.07.14]. [In Chinese]."},{"key":"10.1016\/j.jfma.2015.09.003_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan's new national health insurance program: genesis and experience so far","volume":"22","author":"Cheng","year":"2003","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jfma.2015.09.003_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.1132","article-title":"Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions","volume":"15","author":"Shatin","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jfma.2015.09.003_bib23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2015.09.003_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jfma.2015.09.003_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jfma.2015.09.003_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18553\/jmcp.2013.19.1.49","article-title":"Stubbings, Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty","volume":"19","author":"Hanson","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jfma.2015.09.003_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3201\/eid1602.090675","article-title":"Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000\u20132008","volume":"16","author":"Lai","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jfma.2015.09.003_bib28","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Leon","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2015.09.003_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/pds.3665","article-title":"Prescription patterns for tuberculosis treatment and adherence to treatment guidelines: a population-based study in Taiwan","volume":"23","author":"Wang","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jfma.2015.09.003_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/MLR.0b013e3182a502ba","article-title":"National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report","volume":"51","author":"Chang","year":"2013","journal-title":"Med Care"},{"key":"10.1016\/j.jfma.2015.09.003_bib31","first-page":"S90","article-title":"Laboratory monitoring of biologic therapies","volume":"23","author":"Cush","year":"2005","journal-title":"Clin Exp Rheumatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664615003320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664615003320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T07:36:55Z","timestamp":1599723415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664615003320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0929664615003320"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2015.09.003","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor-\u03b1 therapy in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2015.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier (Singapore) Pte Ltd.","name":"copyright","label":"Copyright"}]}}